Because direct human data on retatrutide and alcohol is still limited, it is best to be cautious
Early rodent data suggests potential for 2832% body weight reduction, but no human trials have commenced
Retatrutide is projected to receive FDA approval in late 2027 or 2028
This could lead to FDA approvals for treatment in obstructive sleep apnea, kidney disease, Alzheimers disease, liver disease, PCOS, and more
Consumers Taking GLP-1s for Weight Loss, Current or Discontinued, Drive Lasting Changes in Retail, Per New Acosta Group Study News provided by Acosta Group Apr 14, 2025, 12:05 ET 76% of those who discontinued GLP-1s are eating the same amount or less and many report retaining healthy habits JACKSONVILLE, Fla., April 14, 2025 /PRNewswire/ -- In advance of the National Association of Chain Drug Stores (NACDS) Annual Meeting, Acosta Group is sharing the results of its recent proprietary GLP-1 Shopper Community study, focusing on consumers using the medications specifically to support weight loss
Talk to your doctor about how often you should visit for follow-ups, including regular monitoring and medication adjustments
